Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
Author:
Funder
Agendia Inc
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology
Link
http://www.nature.com/articles/s41523-019-0109-7.pdf
Reference27 articles.
1. Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784–2795 (2010).
2. Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36, 2105–2122 (2018).
3. Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263–280 (2010).
4. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
5. Viale, G. et al. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Res. Treat. 167, 123–131 (2018).
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy;Molecular Oncology;2023-04-24
2. Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes;Cancers;2022-11-18
3. Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives;Clinical Breast Cancer;2022-10
4. BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance;Breast Cancer Research and Treatment;2022-08-19
5. Reply to W. Altundag;JCO Precision Oncology;2022-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3